Brief: Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved Car-T Products
24/01/2024 16:07
Jan 24 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA STATEMENT ON JANUARY 2024 FDA LABELING
CHANGE
NOTIFICATION FOR APPROVED CAR-T PRODUCTS
* IMMIX BIOPHARMA INC: IN OUR INTERIM CLINICAL DATA TO DATE,
WE
HAVE NOT OBSERVED ANY SECONDARY T-CELL MALIGNANCIES
* IMMIX BIOPHARMA INC: BELIEVE CO'S CAR-T CANDIDATES "WILL
CONTINUE TO EXHIBIT A FAVORABLE TOLERABILITY PROFILE MOVING
FORWARD"
* IMMIX BIOPHARMA INC: BELIEVE NXC-201 WILL BE UNIQUELY
SUITED TO
TREAT AL AMYLOIDOSIS AND OTHER AUTOIMMUNE INDICATIONS
Source text for Eikon: ID:nGNX9h1K2x
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary